Cancer Vaccines Market Overview:
Global Cancer Vaccines Market is expected to reach at $12,814 million from $4,073 million and register a CAGR of 17.7%, during the forecast period, 2017 - 2023.
Vaccine is a biological preparation administered to produce acquired immunity in patients as well as healthy individuals. Cancer vaccines are a type of biological therapy that prevents and heals various types of cancer, such as, cervical cancer, prostate cancer, lung cancer, breast cancer, and others. These vaccines are designed specifically to recognize and reduce the growth of cancer cells by the immune system. Moreover, cancer vaccines are expected to reduce the prevalence and incidence rate of cancer.
The global cancer vaccines market is driven by increase in the prevalence of human papilloma virus (HPV) infections, administration of prophylactic cancer vaccines, high investments & government funding in the development of cancer vaccines, and launch of new cancer vaccines. However, high cost for developing cancer vaccines due to the need for frequently upgradation in manufacturing technology and longer time span required for manufacturing a single vaccine are anticipated to restrict the market growth. Furthermore, growth in transition from prophylactic to therapeutic cancer vaccines are expected to offer lucrative opportunities in the near future.
Global Cancer Vaccines Market Segmentation
The global cancer vaccines market is segmented based on technology, type, indication, end use, and region. Based on technology, it is classified into dendritic cells cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, and viral vector & DNA cancer vaccines. Based on type, it is bifurcated into preventive cancer vaccines and therapeutic cancer vaccines. Based on indication, it is divided into cervical cancer, prostate cancer, and others. Based on end use, it is categorized into pediatric and adult vaccines. Regionally, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
India Cancer Vaccines Market
The pediatric cancer vaccines segment possesses high market potential for growth in the market, owing to increase in traction of prophylactic vaccines among children. However, the adult cancer vaccines segment dominated the global market owing to increase in incidence of human papilloma virus infections in adults, for the forecast period. Furthermore, rise in cancer incidence in India cause approximately 6, 00,0007, 00,000 deaths, thus, growing the need for prophylactic and therapeutic cancer vaccines.
Drivers, Restraints, and Opportunities
The impact of the driving factors is expected to surpass that of the restraints. Moreover, emergence of new markets and increase in transition from prophylactic to therapeutic cancer vaccines is expected to provide new growth opportunities to the cancer vaccines market in the future.
Drivers, Restraints, and Opportunities
The key players profiled in the report are Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.
The other key players in the value chain include Gritstone Oncology, PaxVax Corporation., Bavarian Nordic, Bharat Biotech., VBI Vaccines Inc., Novavax, Inc., Dynavax Technologies Corporation, Immunomic Therapeutics, Inc., Gamma Vaccines Pty Limited, Sinovac Biotech Ltd., Galena Biopharma, Emergent Biosolutions, Prokarium, and ImmunoBiology Ltd.
Key Benefits of the Cancer Vaccines Market Report:
- It provides an in-depth analysis, current trends, and future estimations to elucidate the imminent investment pockets
- It presents a comprehensive analysis of factors that drive and restrict the market growth
- It offers quantitative analysis of the industry to enable the stakeholders to capitalize on the prevailing market opportunities
- It highlights key segments of the industry to help in understanding the type of products and indications used globally
- It profiles key market players and their strategies to comprehend the competitive outlook of the market
Cancer Vaccines Market Key Segments:
- Dendritic Cells (DC) Cancer Vaccines
- Recombinant Cancer Vaccines
- Antigen/Adjuvant Cancer Vaccines
- Whole Cell Cancer Vaccines
- Viral Vector & DNA Cancer Vaccines
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
- Cervical Cancer
- Prostate Cancer
By End Use
- North America
- Rest of Europe
- Rest of Asia-Pacific
- South Africa
- Rest of LAMEA